Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 80

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia80Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Plasma cell myeloma refractory42Follicular lymphoma41Mantle cell lymphoma33Myelofibrosis32B-cell small lymphocytic lymphoma29Chronic myeloid leukaemia29Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17Paroxysmal nocturnal haemoglobinuria17B-cell lymphoma refractory16B-cell type acute leukaemia16Anaemia14+340

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

Acute myeloid leukaemia

Not recruiting

Study of Gilteritinib and Chemotherapy for Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Astellas Pharma Global Development Inc.

Chronic lymphocytic leukaemia

Not recruiting

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study of Venetoclax, Daratumumab, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Thrombotic microangiopathy

Not recruiting

Study of Pegcetacoplan (APL-2) in Patients with Transplant-associated Thrombotic Microangiopathy After Stem Cell Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Chronic lymphocytic leukaemia

Not recruiting

Study on Obinutuzumab and Venetoclax for Elderly Patients with Chronic Lymphocytic Leukemia Unfit for Standard Treatments

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Chronic myeloid leukaemia+2

Not recruiting

Study on the Dose and Safety of Asciminib in Children with Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Asciminib
  • Sponsor:Novartis Pharma AG

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Pirtobrutinib to Bendamustine and Rituximab for Untreated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

B-cell lymphoma+5

Not recruiting

Study on the Effects and Safety of Odronextamab for Adults with Previously Treated B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Odronextamab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Immune thrombocytopenia

Not recruiting

Study on Aspirin (D,L-Lysine Acetylsalicylate) for Patients with Immune Thrombocytopenia and Cardiovascular Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:D,L-Lysine Acetylsalicylate
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Myelofibrosis+1

Not recruiting

Study on the Safety and Effects of Navitoclax and Ruxolitinib for Patients with Myelofibrosis and Myeloproliferative Neoplasms

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Celecoxib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab121 clinical trialsVenetoclax115 clinical trialsCyclophosphamide99 clinical trialsLenalidomide99 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.